SCHEMBL1128064

SCHEMBL1128064

COC(=O)c1ccccc1CN

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
LMNA P02545 2/20 0.62
HSD17B10 Q99714 2/20 0.58
CFTR P13569 1/20 0.58
TSHR P16473 1/20 0.55
KDM4E B2RXH2 2/20 0.52
POLB P06746 2/20 0.52
ATM Q13315 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA5A P35218 1/20 0.51
CA9 Q16790 1/20 0.51
KMT2A Q03164 1/20 0.51
HIF1A Q16665 1/20 0.51
GLA P06280 1/20 0.49
HTT P42858 1/20 0.48
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
LOXL2 Q9Y4K0 2/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25289042 0.98 ALDH1A1 (0.60) ALDH1A1LMNAHSD17B10CFTRTSHR
Hydrochloric Acid SCHEMBL2159177 0.98 ALDH1A1 (0.60) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL3959092 0.86 ALDH1A1 (0.51) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL4739142 0.85 ALDH1A1 (0.68) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL70322 0.84 ALDH1A1 (0.66) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL10360804 0.84 ALDH1A1 (0.77) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL156281 0.84 ALDH1A1 (0.66) ALDH1A1LMNAHSD17B10CFTRTSHR
Hydrochloric Acid SCHEMBL4443950 0.84 ALDH1A1 (0.66) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL1035344 0.84 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10CFTRTSHR
SCHEMBL4443811 0.84 MRGPRX4 (0.50) ALDH1A1LMNAHSD17B10CFTRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109293584-A Target the other structure modulating compound SPAM of small molecule and its preparation method and application of neuropeptide receptor PAC1-R 暨南大学 2019-02-01 CN claimed
CN-107096036-A A kind of preparation method and applications of pH responsive types hyaluronic acid Doxorubicin nano-prodrug 武汉理工大学 2017-08-29 CN claimed
CN-104610166-B Pyrimidine benzyl hydroxamic acid histone deacetylases inhibitor and preparation method and application 山东大学 2017-06-13 CN claimed
CN-104610166-A Pyrimidine benzyl hydroxamic acid histone deacetylase inhibitor, and preparation method and application thereof UNIV SHANDONG 2015-05-13 CN claimed
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
WO-2024201308-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR 주식회사 엘지화학 2024-10-03 WO disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
EP-3844143-B1 TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION GYROS PROTEIN TECH AB (SE) 2024-01-17 EP disclosed
US-11845752-B2 Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B ALIGOS THERAPEUTICS, INC. (US) 2023-12-19 US disclosed
EP-4010352-B1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES GYROS PROTEIN TECH AB (SE) 2023-10-18 EP disclosed
US-6369270-B1 CHEMICAL INTERMEDIATES RHONE POULENC AGRICULTURE LIMITED (GB) 2002-04-09 US disclosed
EP-1182199-A1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2002-02-27 EP disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
CN-1070480-C 2-amino-benzoxanones for the treatment of viral infections SEARLE & CO (US) 2001-09-05 CN disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 ALDH1A1 4342/4885LMNA 1102/4885HSD17B10 2517/4885
US-11845752-B2 Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B SLC10A1, HAVCR2, CYP3A5 ALDH1A1 297/4885LMNA 2492/4885HSD17B10 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.